A new REMAP-CAP paper has just been published! A comprehensive biomarker sub-study in 1239 patients in the REMAP-CAP trial. link.springer.com/article/10.100… Reporting 3 #COVID19 subphenotypes with distinct immunological mechanisms and differences in treatment response to ABO‐compatible high‐titer convalescent plasma therapy. Response to immunotherapies could be enhanced with patient selection based on host immune response patterns.

1. In the Antiplatelet Domain of REMAP-CAP, we aimed to determine whether antiplatelet therapy improves outcomes for critically ill adults with #COVID19.
jamanetwork.com/journals/jama/… 2. 1549 critically ill patients (median age 57 years; 33.6% female) were randomized to either open-label aspirin (n=565), P2Y12 inhibitor (n=455), or no antiplatelet therapy (control, n=529).

The #COVID19 #antiviral domain within @remap_cap has been updated and is already recruiting! Twenty-seven patients have already been randomized. The objective of this domain is to determine the effectiveness of different #antiviral agents for #COVID19 patients.

@remap_cap is proud to announce the findings of IL-6 blockade in critically ill patients with #COVID19.
medrxiv.org/cgi/content/sh… (1/10) 353 patients randomized to #tocilizumab, 48 to #sarilumab, and 402 to control.
Adjusted odds ratio for improvement on organ-support free days at day 21 was 1.64 (CrI 1.25 - 2.18) and 1.89 (1.24 - 3.48), respectively. (2/10)

On the recommendation of the data safety and monitoring board, @REMAP_CAP is declaring efficacy of #tocilizumab with an OR of 1.87 for benefit on a combination of survival and length of time patients received organ support in ICU, compared with standard care [...] This finding has a high degree of statistical certainty, with 99.75% probability of benefit for tocilizumab compared to no immune modulation […]